Nuvation Bio Inc. Class A (NUVB)
NUVB moved a median of -0.21% 30 minutes after news, and +0.21% by the close. How NUVB actually reacts to news — the realized, point-in-time move the market made, measured across 314 labeled events over the last three years with zero look-ahead.
NUVB’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.20% | 43% | 310 |
| 30-min | -0.21% | 47% | 313 |
| 60-min | -0.11% | 47% | 313 |
| to close | +0.21% | 52% | 313 |
| Middle 50% of NUVB reactions | -1.60% to +2.30% |
|---|---|
| Median reaction (30-min) | -0.21% |
| Measured reactions | 314 |
Half of all Nuvation Bio Inc. Class A news events land between -1.60% and +2.30% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NUVB reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 14 | +2.14% | 86% | +5.51% |
| Coverage initiations | 26 | +1.47% | 62% | +2.71% |
| Rating reiterations | 91 | +0.26% | 52% | -0.27% |
| Price-target raises | 12 | +0.09% | 50% | -0.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how NUVB ranks against every other measured name →
That’s how NUVB usually reacts — get an email when it moves on news →Email me when NUVB moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NUVB's baseline. Nothing else.
Recent NUVB events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer | Press release | PR Newswire | +0.42% | +2.53% | |
| Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer | Press release | PR Newswire | +0.00% | -1.70% | |
| Nuvation Bio to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -0.85% | -3.70% | |
| Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant Glioma | Press release | PR Newswire | -1.86% | -5.79% | |
| Form 10-Q Nuvation Bio Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.95% | +0.82% | |
| Form 8-K Nuvation Bio Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +4.95% | +0.82% | |
| Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | +4.95% | +0.82% | |
| Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses | Press release | PR Newswire | -0.64% | +2.71% | |
| Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026 | Press release | PR Newswire | -0.70% | +1.09% | |
| Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Glioma | Press release | PR Newswire | +2.90% | +6.64% | |
| Form 8-K Nuvation Bio Inc. For: Jun 30 | SEC filing · Form 8-K | SEC EDGAR | +0.09% | -0.18% | |
| Nuvation Bio Inc. Announces Full Exercise of Greenshoe Option in $287.5 Million Convertible Senior Notes Offering | Press release | PR Newswire | +0.09% | -0.18% | |
| Form 8-K Nuvation Bio Inc. For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +2.11% | -4.58% | |
| Form 305B2 Nuvation Bio Inc. | SEC filing · Form 305B2 | SEC EDGAR | +0.18% | +0.00% | |
| Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom | Press release | PR Newswire | +0.18% | +0.00% | |
| Nuvation Bio Announces Pricing of Upsized Offering of $250.0 million of Convertible Senior Notes | Press release | PR Newswire | -3.27% | -2.75% | |
| Nuvation Bio Announces Proposed Convertible Senior Notes Offering | Press release | PR Newswire | +2.96% | +5.64% | |
| Form 8-K Nuvation Bio Inc. For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.42% | +0.42% | |
| Nuvation Bio to Present at the Jefferies Global Healthcare Conference | Press release | PR Newswire | -0.42% | +0.42% | |
| Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting | Press release | PR Newswire | -0.97% | +0.21% | |
| Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer | Press release | PR Newswire | -0.93% | -2.08% | |
| Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer | Press release | PR Newswire | +0.20% | +1.82% | |
| Nuvation Bio to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.20% | +1.82% | |
| Form 10-Q Nuvation Bio Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.91% | +9.28% | |
| Form 8-K Nuvation Bio Inc. For: May 04 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | +9.28% | |
| Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | PR Newswire | -0.91% | +9.28% | |
| Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers | Press release | PR Newswire | -0.82% | -6.37% | |
| Form DEFA14A Nuvation Bio Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.20% | -0.49% | |
| Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026 | Press release | PR Newswire | -0.67% | -2.66% | |
| Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026 | Press release | PR Newswire | +0.58% | -0.58% | |
| Form ARS Nuvation Bio Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.11% | +1.54% | |
| Form DEF 14A Nuvation Bio Inc. For: May 21 | SEC filing · Form DEF | SEC EDGAR | -0.33% | +1.43% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Nuvation Bio Inc. (NUVB) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.11% | +0.67% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | +0.11% | -3.68% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | -0.44% | -1.77% | |
| Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.11% | -2.76% | |
| Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo | Press release | PR Newswire | +3.42% | +2.97% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.96% | +3.13% | |
| Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.70% | -4.71% | |
| Nuvation Bio Inc. (NUVB) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.46% | -2.63% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nuvation Bio Inc. (NUVB) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.11% | +0.57% | |
| Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency | Press release | PR Newswire | +1.83% | -2.75% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Nuvation Bio Inc. (NUVB) Investors to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -0.57% | |
| Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026 | Press release | PR Newswire | +0.46% | -0.70% | |
| Form S-8 Nuvation Bio Inc. | SEC filing · Form S-8 | SEC EDGAR | -2.92% | +6.28% | |
| Form 10-K Nuvation Bio Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -8.61% | -8.40% | |
| Form 8-K Nuvation Bio Inc. For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | -8.61% | -8.40% | |
| Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Press release | PR Newswire | -8.61% | -8.40% | |
| Nuvation Bio to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +0.01% | +4.50% | |
| Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026 | Press release | PR Newswire | +1.12% | -0.52% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NUVB section they belong to.
Where else NUVB is measured.
NUVB earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nuvation Bio Inc. Class A's median reaction calculated?
Every labeled NUVB news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 314 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of NUVB's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NUVB's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.